第713号委员会意见:促进胎肺成熟的产前糖皮质激素治疗
该委员会意见明确产前糖皮质激素是改善新生儿结局最重要的产前治疗之一。推荐对孕24 0/7至33 6/7周、7天内可能早产者(包括胎膜已破和多胎妊娠)给予单疗程糖皮质激素。孕23 0/7周起、7天内可能早产者,可基于家庭对复苏的决定考虑使用,不论胎膜是否破裂及胎儿数目。孕34 0/7至36 6/7周、7天内可能早产且既往未接受过产前糖皮质激素者,可考虑倍他米松。对小于34 0/7周、7天内可能早产且前次疗程已超过14天者,应考虑单次重复疗程;如有临床指征,补救疗程最早可在前次给药后7天给予。
要点
- 孕24 0/7至33 6/7周、7天内可能早产者推荐单疗程糖皮质激素,包括胎膜已破和多胎妊娠。
- 孕23 0/7周起、7天内可能早产者,可基于家庭对复苏的决定考虑糖皮质激素,不论胎膜是否破裂及胎儿数目。
- 孕34 0/7至36 6/7周、7天内可能早产且既往未用过产前糖皮质激素者,可考虑倍他米松。
- 小于34 0/7周、7天内可能早产且前次疗程超过14天者,应考虑单次重复疗程;有指征时补救疗程最早可在前次给药后7天给予。
- 应支持对宫内糖皮质激素暴露后长期结局的持续监测,并鼓励采用质量改进策略优化及时、恰当的产前糖皮质激素给药。
适用人群与场景
- 孕24 0/7至33 6/7周、7天内可能早产者,包括胎膜已破和多胎妊娠。
- 孕23 0/7周起、7天内可能早产者,基于家庭对复苏的决定考虑使用,不论胎膜是否破裂及胎儿数目。
- 孕34 0/7至36 6/7周、7天内可能早产且既往未接受过产前糖皮质激素疗程者。
- 小于34 0/7周、7天内可能早产且前次产前糖皮质激素疗程已超过14天者(考虑单次重复疗程)。
处置流程与药物剂量
- 孕24 0/7至33 6/7周、7天内可能早产者:推荐单疗程糖皮质激素(包括胎膜已破和多胎妊娠)。
- 孕23 0/7周起、7天内可能早产者:可基于家庭对复苏的决定考虑糖皮质激素,不论胎膜是否破裂及胎儿数目。
- 孕34 0/7至36 6/7周、7天内可能早产且既往未接受过产前糖皮质激素者:可考虑倍他米松。
- 小于34 0/7周、7天内可能早产且前次疗程超过14天者:应考虑单次重复疗程。
- 补救疗程糖皮质激素:如有临床指征,最早可在前次给药后7天给予。
研究设计与关键结果
- 该文件为美国妇产科医师学会(American College of Obstetricians and Gynecologists)第713号委员会意见,阐述产前糖皮质激素用于促进胎肺成熟的推荐。
证据类型、等级与局限
- 证据类型:委员会意见(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对孕24 0/7至33 6/7周、7天内可能早产者(含胎膜已破和多胎妊娠),按推荐给予单疗程产前糖皮质激素。
- 对孕23 0/7周起、7天内可能早产者,可结合家庭对复苏的决定考虑糖皮质激素,不论胎膜是否破裂及胎儿数目。
- 对孕34 0/7至36 6/7周、7天内可能早产且既往未用过产前糖皮质激素者,可考虑倍他米松。
- 对小于34 0/7周、7天内可能早产且前次疗程超过14天者,考虑单次重复疗程;有临床指征时补救疗程最早可在前次给药后7天给予。
- 鼓励采用质量改进策略优化产前糖皮质激素的恰当与及时给药,并支持对宫内暴露后长期结局的持续监测。
指南或共识出处
- Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation(Obstet Gynecol)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Corticosteroid administration before anticipated preterm birth is one of the most important antenatal therapies available to improve newborn outcomes. A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, including for those with ruptured membranes and multiple gestations. It also may be considered for pregnant women starting at 23 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, based on a family's decision regarding resuscitation, irrespective of membrane rupture status and regardless of fetal number. Administration of betamethasone may be considered in pregnant women between 34 0/7 weeks and 36 6/7 weeks of gestation who are at risk of preterm birth within 7 days, and who have not received a previous course of antenatal corticosteroids. A single repeat course of antenatal corticosteroids should be considered in women who are less than 34 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously. Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario. Continued surveillance of long-term outcomes after in utero corticosteroid exposure should be supported. Quality improvement strategies to optimize appropriate and timely antenatal corticosteroid administration are encouraged.
参考来源
- Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017. PMID: 28742678. doi:10.1097/AOG.0000000000002237
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。